| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Ipsen's Iqirvo receives FDA approval to treat adults with primary biliary cholangitis | 1 | PMLiVE | ||
| Di | FDA clears Ipsen's primary biliary cholangitis drug | - | pharmaphorum | ||
| Di | FDA gives accelerated approval for Ipsen's Iqirvo for primary biliary cholangitis | 1 | Pharmaceutical Technology | ||
| Di | Ipsen's Iqirvo Secures FDA Accelerated Approval For Primary Biliary Cholangitis Treatment | 1 | RTTNews | ||
| Mo | GENFIT S.A.: Historic Milestone Achieved with U.S. FDA Accelerated Approval of Ipsen's Iqirvo for Primary Biliary Cholangitis | 106 | GlobeNewswire (Europe) | Ipsen's Iqirvo® (elafibranor) 80 mg tablets receives U.S. FDA accelerated approval as a first-in-class treatment for Primary Biliary Cholangitis (PBC)First-ever drug developed in-house by GENFIT to... ► Artikel lesen | |
| Mo | Ipsen Pharma: Ipsen's Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis | 331 | GlobeNewswire (Europe) | Iqirvo® (elafibranor) 80 mg tablets is the first new medicine approved in nearly a decade for the treatment of the rare liver... ► Artikel lesen | |
| Mo | Tharimmune, Inc.: Tharimmune Announces Positive Results of Phase 1 Trial in Healthy Subjects with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis | 137 | ACCESSWIRE | Pharmacokinetic profile of oral transmucosal delivery of TH104 was comparable to intravenous delivery of reference drugPositive safety/tolerability achieved with TH104 reporting a mild side-effect profilePlanning... ► Artikel lesen | |
| Mo | Zymeworks Inc.: Zymeworks Announces China NMPA Acceptance of Biologics License Application for Zanidatamab for Second-Line Treatment of Biliary Tract Cancer | 196 | GlobeNewswire (Europe) | Pursuant to the terms of the licensing agreement between Zymeworks and BeiGene, Zymeworks is entitled to receive an $8 million milestone payment from BeiGene and remains eligible to receive up to $164... ► Artikel lesen | |
| 05.06. | Gilead Announces Long-term Safety And Efficacy Data For Seladelpar In Primary Biliary Cholangitis | 346 | AFX News | FOSTER CITY (dpa-AFX) - Gilead Sciences, Inc. (GILD) Wednesday announced positive results from two-year interim analysis of the ongoing ASSURE study evaluating the company's investigational... ► Artikel lesen | |
| 05.06. | Ipsen Pharma: Ipsen presents long-term elafibranor efficacy and itch-related quality of life data in patients with primary biliary cholangitis | 332 | GlobeNewswire (Europe) | New data from the ELATIVE® Phase III trial show 70% of patients treated with elafibranor achieved composite endpoint of slowing disease progression measured by biochemical response after 78-weeksData... ► Artikel lesen | |
| 05.06. | Gilead Sciences, Inc.: Gilead's Seladelpar Demonstrated a Sustained and Consistent Long-Term Efficacy and Safety Profile in Primary Biliary Cholangitis | 371 | Business Wire | - Positive Results from Two-year Interim Analysis Includes Participants from Phase 3 RESPONSE Study and are Highly Consistent with One-year Interim Analysis - - Reduction in Patient-Reported... ► Artikel lesen | |
| 01.06. | Jazz presents additional phase 2 data on zanidatamab for biliary tract cancer | 1 | Seeking Alpha | ||
| 01.06. | ASCO: Jazz shares 'unprecedented' HER2 biliary tract cancer data ahead of FDA decision | 1 | FierceBiotech | ||
| 01.06. | Jazz Presents Overall Survival & Longer Data From Trial Of Zanidatamab In Biliary Tract Cancer | 1 | RTTNews | ||
| 01.06. | Jazz Pharmaceuticals plc: Jazz Pharmaceuticals Presents Overall Survival and Longer Follow-Up Data from HERIZON-BTC-01 Trial Evaluating Zanidatamab in Previously Treated HER2-Positive Biliary Tract Cancer at ASCO 2024 | 38 | PR Newswire | Zanidatamab demonstrated a median overall survival (OS) of 15.5 months in patients with centrally confirmed immunohistochemistry (IHC) 2+ or 3+ and a median OS of 18.1 months in patients with IHC 3+... ► Artikel lesen | |
| 21.05. | Gilead's investigational seladelpar shows promise in primary biliary cholangitis | 5 | PMLiVE | ||
| 09.05. | Merck' Keytruda Receives Approval From Health Canada For Biliary Tract Carcinoma In Adults | 261 | AFX News | KENILWORTH (NJ) (dpa-AFX) - Thursday, Merck & Co., Inc. (MRK) announced that Health Canada has approved Keytruda, also known as pembrolizumab, for the treatment of adult patients with locally... ► Artikel lesen | |
| 09.05. | Health Canada Approves KEYTRUDA for adult patients with locally advanced unresectable or metastatic biliary tract carcinoma, in combination with gemcitabine-based chemotherapy | 1 | CNW | ||
| 25.04. | Compass gains FDA Fast Track status for biliary tract cancer candidate | 1 | Seeking Alpha | ||
| 24.04. | Bilia AB: Bulletin from Bilia's annual general meeting 2024 | 1.662 | GlobeNewswire (Europe) | Bilia AB's AGM took place on Wednesday, 24 April 2024. Adoption of the profit and loss statement and balance sheet The profit and loss statements and the balance sheets of the parent company and the... ► Artikel lesen |
Seite:
1 2 Weiter >>
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| NVIDIA | 825 |
| RHEINMETALL | 503 |
| TUI | 488 |
| GAMESTOP | 474 |
| EVOTEC | 369 |
| DEUTSCHE LUFTHANSA | 368 |
| NEL | 342 |
| SNOWFLAKE | 300 |
| BAYER | 299 |
| TESLA | 283 |
| BYD | 264 |
| BASF | 210 |
| VOLKSWAGEN | 200 |
| APPLE | 188 |
| DEUTSCHE TELEKOM | 187 |
| PORSCHE SE | 187 |
| MERCEDES-BENZ | 166 |
| THYSSENKRUPP | 162 |
| ALLIANZ | 154 |
| DEUTSCHE BANK | 145 |
| PLUG POWER | 135 |
| BROADCOM | 134 |
| COMMERZBANK | 134 |
| MICROSOFT | 126 |
| RWE | 126 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
